The downregulation of AGER was significantly correlated with tumor histology, stage, lymph node metastasis, and TP53 mutation of LUAD and LUSC patients (Figures 1(c) and 1(d)). Here, TP53 is linked to metastatic malignant neoplasm in the lymph nodes.